High Blood Pressure & Cardiovascular Prevention

, Volume 10, Issue 1, pp 19–25

Is Endothelial Dysfunction a Measurable Endpoint in Hypertension?

  • Stefano Taddei
  • Agostino Virdis
  • Lorenzo Ghiadoni
  • Daniele Versari
  • Antonio Salvetti
Review Article
  • 19 Downloads

Abstract

Endothelium plays a primary role in the local control of vascular function and structure. Thus endothelium-derived nitric oxide (NO) is not only a potent vasodilator but also inhibits platelet aggregation, vascular smooth muscle cell migration and proliferation, monocyte adhesion and adhesion molecule expression, thus protecting the vessel wall against the development of atherosclerosis and thrombosis. Essential hypertension is associated with endothelial dysfunction, which involves the enhanced production of oxygen free radicals, that can destroy NO and reduce its availability, and the release of endothelium-derived contracting factors, including prostanoids and endothelin-1.

Endothelial dysfunction in patients with essential hypertension is, at least in part, genetically determined and shows no correlation with blood pressure load, but is a promoter of atherosclerotic and thrombotic damage, which are typical complications of hypertension. In prospective studies, impaired endothelium-dependent vasodilation is associated with an increased incidence of cardiovascular events. Thus, endothelial dysfunction is often considered a target for cardiovascular treatment. However, endothelial function cannot yet be included among the surrogate endpoints that need to be measured for cardiovascular risk stratification in patients with essential hypertension because of the lack of validated tests. Currently, the tests available for assessing endothelium-dependent vasodilation are invasive or, if not invasive, do not have sufficient sensitivity and specificity for clinical practice. Moreover, despite considerable evidence that impaired endothelium-dependent vasodilation can be improved by the appropriate antihypertensive treatment, further large-scale clinical trials are required to prove conclusively whether reversal of endothelial dysfunction offers a clinical advantage in patients with essential hypertension. Only after a specific and affordable test has been validated, and definite evidence becomes available to demonstrate that endothelial dysfunction must be a target of pharmacological treatment, will the evaluation of endothelium-dependent vasodilation be included in the list of clinical examinations that define cardiovascular risk in patients with essential hypertension.

References

  1. 1.
    Furchgott RF, Zawadzky JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373–6PubMedCrossRefGoogle Scholar
  2. 2.
    Luscher TF, Vanhoutte PM. The endothelium: modulator of cardiovascular function. Boca Raton (FL): CRC Press, 1990Google Scholar
  3. 3.
    Cohen RA, Vanhoutte PM. Endothelium-dependent hyperpolarization-beyond nitric oxide and cyclic GMP. Circulation 1995; 92: 3337–49PubMedCrossRefGoogle Scholar
  4. 4.
    Haynes WG, Webb DJ. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 1998; 16: 1081–98PubMedCrossRefGoogle Scholar
  5. 5.
    Panza JA, Quyyumi AA, Brush Jr JE, et al. Abnormal endothelium dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22–7PubMedCrossRefGoogle Scholar
  6. 6.
    John S, Schmieder RE. Impaired endothelial function in arterial hypertension and hypercholesterolemia: potential mechanisms and differences. J Hypertens 2000; 18: 363–74PubMedCrossRefGoogle Scholar
  7. 7.
    Taddei S, Virdis A, Ghiadoni L, et al. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 1998; 97: 2222–9PubMedCrossRefGoogle Scholar
  8. 8.
    Taddei S, Virdis A, Ghiadoni L, et al. Cyclooxygenase inhibition restrores nitric oxide activity in essential hypertension. Hypertension 1997; 29(1 Pt 2): 274–9PubMedCrossRefGoogle Scholar
  9. 9.
    Cardillo C, Kilcoyne CM, Cannon RO, et al. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension 1997; 30(1 Pt 1): 57–63PubMedCrossRefGoogle Scholar
  10. 10.
    Taddei S, Ghiadoni L, Virdis A, et al. Vasodilation to bradykinin is mediated by an ouabain-sensitive pathway as a compensatory mechanism for impaired NO availability in essential hypertensive patients. Circulation 1999; 100: 1400–5PubMedCrossRefGoogle Scholar
  11. 11.
    Schiffrin EL. Role of endothelin-1 in hypertension. Hypertension 1999; 34(Pt 2): 876–81PubMedCrossRefGoogle Scholar
  12. 12.
    Taddei S, Virdis A, Ghiadoni L, et al. Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension. Circulation 1999; 100: 1680–3PubMedCrossRefGoogle Scholar
  13. 13.
    Taddei S, Virdis A, Mattei P, et al. Defective L-arginine-nitric oxide pathway in offspring of essential hypertensive patients. Circulation 1996; 94(6): 1298–303PubMedCrossRefGoogle Scholar
  14. 14.
    Rossi GP, Taddei S, Virdis A, et al. The T−786C and Glu298ASP polymorphisms of the endothelial nitric oxide gene affect the forearm blood flow responses of caucasian hypertensive patients. J Am Coll Cardiol 2003; 41: 938–48PubMedCrossRefGoogle Scholar
  15. 15.
    Taddei S, Virdis A, Mattei P, et al. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation 1995; 91(7): 1981–7PubMedCrossRefGoogle Scholar
  16. 16.
    Panza JA, Quyyumi AA, Callahan TS, et al. Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol 1993; 21(5): 1145–51PubMedCrossRefGoogle Scholar
  17. 17.
    Taddei S, Virdis A, Ghiadoni L, et al. Effects of antihypertensive drugs on endothelial dysfunction: clinical implications. Drugs 2002; 62(2): 265–84PubMedCrossRefGoogle Scholar
  18. 18.
    Taddei S, Salvetti A. Endothelial dysfunction in essential hypertension: clinical implications. J Hypertens 2002; 20: 1671–4PubMedCrossRefGoogle Scholar
  19. 19.
    Vita JA, Treasure CB, Nabel EG, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990; 81: 491–7PubMedCrossRefGoogle Scholar
  20. 20.
    Drexler H. Endothelial dysfunction: clinical implications. Prog Cardiovasc Dis 1997; 39: 287–324PubMedCrossRefGoogle Scholar
  21. 21.
    Ghiadoni L, Taddei S, Virdis A, et al. Endothelial function and common carotid artery wall thickening in patients with essential hypertension. Hypertension 1998; 32: 25–32PubMedCrossRefGoogle Scholar
  22. 22.
    Zeiher AM, Schachlinger V, Hohnloser SH, et al. Coronary atherosclerotic wall thickening and vascular reactivity in humans: elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. Circulation 1994; 89: 2525–32PubMedCrossRefGoogle Scholar
  23. 23.
    Davis SF, Yeung AC, Meredith IT, et al. Early endothelial dysfunction predicts the development of transplant coronary artery disease at 1 year posttransplant. Circulation 1996; 93: 457–62PubMedCrossRefGoogle Scholar
  24. 24.
    Hollemberg SM, Klein LW, Parrillo JE, et al. Coronary endothelial dysfunction after heart transplantation predicts allograft vasculopathy and cardiac death. Circulation 2001; 104: 3091–6CrossRefGoogle Scholar
  25. 25.
    Suwaidi JA, Hamasaki S, Higano ST, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948–54PubMedCrossRefGoogle Scholar
  26. 26.
    Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899–906PubMedCrossRefGoogle Scholar
  27. 27.
    Neunteufl T, Heher S, Katzenschlager R, et al. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol 2000; 86(2): 207–10PubMedCrossRefGoogle Scholar
  28. 28.
    Heitzer T, Schlinzig T, Krohn K, et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events with coronary artery disease. Circulation 2001; 104: 2673–8PubMedCrossRefGoogle Scholar
  29. 29.
    Halcox JP, Schenke WH, Zalos G, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002; 106: 653–8PubMedCrossRefGoogle Scholar
  30. 30.
    Gokce N, Keaney Jr JF, Hunter LM, et al. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 2002; 105: 1567–72PubMedCrossRefGoogle Scholar
  31. 31.
    Rossi GP, Cesari M, Zanchetta M, et al. The T(-786)C endothelial nitric oxide synthase genotype is a novel risk factor for coronary artery disease in Caucasian patients of the GENICA study. J Am Coll Cardiol 2003; 41: 930–7PubMedCrossRefGoogle Scholar
  32. 32.
    Perticone F, Ceravolo R, Pujia A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104: 191–6PubMedCrossRefGoogle Scholar
  33. 33.
    Solzbach U, Hornig B, Jeserich M, et al. Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients. Circulation 1997; 96: 1513–9PubMedCrossRefGoogle Scholar
  34. 34.
    Lüscher TF, Noll G. Endothelial function as an end-point in intervention trials: concepts, methods and current data. J Hypertens 1996; 14Suppl. 2: S111–21CrossRefGoogle Scholar
  35. 35.
    Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995; 26: 1235–41PubMedCrossRefGoogle Scholar
  36. 36.
    Ross R. Atherosclerosis: an inflammatory disease? N Engl J Med 1999; 340: 115–26PubMedCrossRefGoogle Scholar
  37. 37.
    Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557–65PubMedCrossRefGoogle Scholar
  38. 38.
    Fichtlscherer S, Rosenberger G, Walter DH, et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000; 102(9): 1000–6PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Hypertension 2003

Authors and Affiliations

  • Stefano Taddei
    • 1
  • Agostino Virdis
    • 1
  • Lorenzo Ghiadoni
    • 1
  • Daniele Versari
    • 1
  • Antonio Salvetti
    • 1
  1. 1.Department of Internal MedicineUniversity of PisaPisa, 67Italy

Personalised recommendations